Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf 'unlimited' therapeutic agent: results from the Acute Myocardial Infarction First-in-Man Study.

Musialek, Piotr; Mazurek, Adam; Jarocha, Danuta; Tekieli, Lukasz; Szot, Wojciech; Kostkiewicz, Magdalena; Banys, R Pawel; Urbanczyk, Malgorzata; Kadzielski, Andrzej; Trystula, Mariusz; Kijowski, Jacek; Zmudka, Krzysztof; Podolec, Piotr; Majka, Marcin

doi:10.5114/pwki.2015.52282

Record: found
Abstract: found
Article: not found

Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf 'unlimited' therapeutic agent: results from the Acute Myocardial Infarction First-in-Man Study.

Author(s): Piotr Musialek, Adam Mazurek, Danuta Jarocha, Lukasz Tekieli, Wojciech Szot, Magdalena Kostkiewicz, R Pawel Banys, Malgorzata Urbanczyk, Andrzej Kadzielski, Mariusz Trystula, Jacek Kijowski, Krzysztof Zmudka, Piotr Podolec, Marcin Majka

Publication date: 2015

Journal: Postepy w kardiologii interwencyjnej = Advances in interventional cardiology

Publisher: Termedia Sp. z.o.o.

Keywords: Wharton's jelly mesenchymal stem cells, acute myocardial infarction, first-in-man, myocardial regeneration, human umbilical cord matrix, safety, feasibility

Read this article at

ScienceOpenPublisher PMC

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In large-animal acute myocardial infarction (AMI) models, Wharton's jelly (umbilical cord matrix) mesenchymal stem cells (WJMSCs) effectively promote angiogenesis and drive functional myocardial regeneration. Human data are lacking.